Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Exelixis, Inc.    EXEL

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/24/2017 04/25/2017 04/26/2017 04/27/2017 04/28/2017 Date
21.3(c) 22.08(c) 22(c) 22.24(c) 22.4(c) Last
2 666 263 3 668 444 2 831 632 2 247 513 2 468 510 Volume
+1.53% +3.66% -0.36% +1.09% +0.72% Change
More quotes
Financials ($)
Sales 2017 321 M
EBIT 2017 20,9 M
Net income 2017 14,7 M
Finance 2017 90,1 M
Yield 2017 -
Sales 2018 513 M
EBIT 2018 155 M
Net income 2018 152 M
Finance 2018 233 M
Yield 2018 -
P/E ratio 2017 491,23
P/E ratio 2018 45,51
EV / Sales2017 20,1x
EV / Sales2018 12,3x
Capitalization 6 548 M
More Financials
Company
Exelixis, Inc. is a biopharmaceutical company, which engages in the developing and commercializing small molecule therapies for the treatment of cancer.Its brands include COMETRIQ and cobimetinib.The company focuses on their proprietary resources and development and commercialization of... 
More about the company
Surperformance© ratings of Exelixis, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on EXELIXIS, INC.
04/24 EXELIXIS : to Present at the Deutsche Bank 42nd Annual Health Care Conference on..
04/18 EXELIXIS : to Release First Quarter 2017 Financial Results on Monday, May 1, 201..
04/04 EXELIXIS : Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04/01 INSIDER TRADING ACTIVITY EXELIXIS, I : EXEL) – Director Sold 5,150 shares ..
03/29 EXELIXIS : Further Reduces Indebtedness by Repaying Silicon Valley Bank Term Loa..
03/29 INSIDER TRADING ACTIVITY EXELIXIS, I : EXEL) – EVP Sold 6,884 shares of St..
03/27 EXELIXIS : to Present at the Needham & Company Healthcare Conference on April 4
03/25 INSIDER TRADING ACTIVITY EXELIXIS, I : EXEL) – EVP Sold 23,787 shares of S..
03/16 EXELIXIS, INC. : When Profit Makers Can Be Active Profit Takers
03/15 INSIDER TRADING ACTIVITY EXELIXIS, I : EXEL) – Director Sold 10,000 shares..
More news
Sector news : Bio Therapeutic Drugs
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on EXELIXIS, INC. 
2013A downturn could form
More Strategies
Latest Tweets
04/27$EXEL OPENING MAY BULL BET DETECTED ..
1
04/27Exelixis, Inc. $EXEL Shares Sold by Acadian Asset Management LLC  
04/26Exelixis (EXEL) Q1 Earnings: Will the Stock Disappoint? -  
04/25Candriam Luxembourg S.C.A. Has $4.833 Million Position in Exelixis, Inc. $EXE.. 
04/24Exelixis : to Present at the Deutsche Bank 42nd Annual Health Care Conference.. 
More tweets
Qtime:40
News from SeekingAlpha
04/30 Notable earnings after Monday?s close
04/18 A Dry Run For Novartis And Allergan's Liver Disease Assets
03/31 Premarket analyst action - healthcare
03/25 MARKETPLACE ROUNDTABLE : Biotech Hanging In The Balance
03/22 Best Price-Positioned Integrated Oil & Gas Stocks, As Seen By Market-Makers
Advertisement
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | EXEL | US30161Q1040 | 4-Traders
Full-screen chart
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 25,6 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael M. Morrissey President, Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Christopher J. Senner Chief Financial Officer & Executive Vice President
Gisela M. Schwab Chief Medical Officer & President-Medical Affairs
Peter Lamb Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
EXELIXIS, INC.50.23%6 548
AMGEN, INC.11.70%120 105
CELGENE CORPORATION7.17%96 861
GILEAD SCIENCES, INC.-4.27%89 611
REGENERON PHARMACEUTIC..5.83%41 293
VERTEX PHARMACEUTICALS..60.58%29 390
More Results